Evidence map›Paper›PMID 41181332›Full record

ArticleFrontiers in cellular and infection microbiology2025

Proteomic landscape of imipenem resistance in

Marius Eidsaa, Animesh Sharma, Markus Janasch, Alicja Kuch, Anna Skoczyńska, Francesca Di Bartolomeo

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Marius EidsaaDepartment of Biotechnology and Nanomedicine, SINTEF Industry, Trondheim, Norway.
Animesh SharmaDepartment of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
Markus JanaschDepartment of Biotechnology and Nanomedicine, SINTEF Industry, Trondheim, Norway.
Alicja KuchDepartment of Epidemiology and Clinical Microbiology, National Medicines Institute (NMI), Warsaw, Poland.
Anna SkoczyńskaDepartment of Epidemiology and Clinical Microbiology, National Medicines Institute (NMI), Warsaw, Poland.
Francesca Di BartolomeoDepartment of Biotechnology and Nanomedicine, SINTEF Industry, Trondheim, Norway.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The increasing prevalence of antimicrobial resistance (AMR) poses a significant challenge to global health, particularly with bacterial pathogens such as

Indexed as

Anti-Bacterial AgentsBacterial ProteinsDrug Resistance, BacterialImipenemProteomePseudomonas aeruginosaBiofilmsHumansMicrobial Sensitivity TestsProteomicsPseudomonas InfectionsAnti-Bacterial AgentsBacterial ProteinsImipenemProteomeantibiotic challengeantimicrobial resistanceimipenemlabel-free quantitative proteomicsPseudomonas aeruginosa

Identifiers

PMID41181332
PMCPMC12571913

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.